98%
921
2 minutes
20
Objective: To investigate the clinical effect of extraperitoneal robot-assisted laparoscopic modified Y-V plasty (LMYVP) in the treatment of refractory bladder neck contracture (BNC).
Methods: We retrospectively analyzed the clinical data on 10 cases of refractory BNC after transurethral resection of the prostate between September 2020 and January 2023, all with a history of recurrent urethral dilatation and at least two failures in transurethral surgical treatment of scarring. After definite diagnosis and removal of some of the scar tissues to flatten the elevated bladder neck under the cystoscope, we performed robot-assisted LMYVP using the da Vinci Si robotic system and a four-port extraperitoneal approach. The surgical procedure involved an inverted T-shaped incision in the bladder neck and urethral stricture ring, an inverted V-shaped excision of the scar area at the 3-9 o'clock position on the ventral side of the prostatic urethra, continuous full-layer suturing of the bladder neck and inverted V-shaped urethra with 3-0 barbed thread, and indwelling of an F20 silicone catheter for 2 weeks. At 3 months after surgery, we performed cystoscopic examination, measured the maximum urinary flow rate (Qmax), and obtained the IPSS and quality of life (QOL) scores of the patients.
Results: Operations were successfully completed in all the cases. At 3 months after surgery, the patients showed significantly increased Qmax ([3.65 ± 1.27] vs [20.3 ± 1.77] ml/s, P < 0.05), IPSS (5.9 ± 2.02 vs 30 ± 1.15, P < 0.05) and QOL score (1.3 ± 0.95 vs 5.2 ± 0.79, P < 0.05) compared with the baseline. Cystoscopy revealed a wide and flat bladder neck with good survival and hemodynamics of the bladder flap. All the patients met the criteria for clinical cure at a median follow-up of 13.2 months.
Conclusion: Extraperitoneal robot-assisted LMYVP provides a new strategy for urinary tract reconstruction in the management of refractory BNC, with the advantages of minimal invasiveness, high efficiency and high success rate.
Download full-text PDF |
Source |
---|
Clin Pharmacol Drug Dev
September 2025
Phase I Clinical Research Centre, Wuhan Pulmonary Hospital, Wuhan, China.
Tamsulosin is a highly selective α1A adrenergic receptor antagonist that can relax smooth muscles in the urethra, bladder neck, and prostate and improve urinary disorders. It is therefore widely used to treat lower urinary tract symptoms caused by benign prostatic hyperplasia. The aim of this study is to evaluate the pharmacokinetic (PK) characteristics and bioequivalence of 2 different formulations (tamsulosin sustained-release tablets and tamsulosin sustained-release capsules) in healthy Chinese subjects.
View Article and Find Full Text PDFCurr Opin Urol
September 2025
Department of Surgery, Urology Division, University of Toronto, Toronto, Ontario, Canada.
Purpose Of Review: The expanding range of minimally invasive surgical therapies (MISTs) for benign prostatic hyperplasia (BPH) reflects a growing emphasis on individualized, anatomy-driven treatment that prioritizes symptom relief, reduced morbidity, and preservation of sexual function. This review provides a timely synthesis of MISTs, highlighting innovations in technique, key anatomical considerations, and evolving strategies for patient-centered care in the modern clinical setting.
Recent Findings: Recent studies highlight the expanding role of MISTs, such as UroLift, Rezūm, the temporary implanted nitinol device, Optilume BPH, transperineal laser ablation, and prostatic stents.
Cureus
August 2025
Agriculture Extension, Muhammad Nawaz Shareef University of Agriculture, Multan, PAK.
Background: Bladder outlet obstruction (BOO) due to benign prostatic hyperplasia (BPH) is a common urological condition in aging men, often requiring surgical intervention for symptom relief.
Objective: To evaluate the therapeutic efficacy and complication profile of monopolar transurethral resection of the prostate (TURP) in patients with BOO.
Methodology: This descriptive observational study was conducted at the Department of Urology, Hayatabad Medical Complex, Peshawar, and Akhtar Saeed Trust Hospital, Lahore, from August 2022 to July 2024.
Res Rep Urol
September 2025
Department of Urology, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
Background: Non-epithelial bladder neoplasms are rare, and there are only approximately 250 cases of bladder leiomyoma reported in the English literature. We present a case of bladder leiomyoma in a patient with recurrent acute cystitis.
Case Presentation: A 53-year-old woman presented to a local clinic with frequent urination and dysuria and was diagnosed with acute cystitis.
Pract Radiat Oncol
September 2025
Department of Radiation Oncology, Institut Bergonié, Bordeaux, France; Centre de Radiothérapie Charlebourg, La Défense, Groupe Amethyst, 65, avenue Foch, 92250 La Garenne-Colombes, France.
Purpose: Urinary toxicity following radical prostatectomy (RP) and postoperative radiotherapy (RT) includes urinary incontinence and vesicourethral anastomosis (VUA) strictures. With the increasing use of stereotactic body radiotherapy (SBRT), dose-escalation, and reirradiation within the prostate bed (PB), standardization of the definition of urinary organs at risk (OARs) in the post-RP setting is needed. This works aims to provide a comprehensive review of the anatomical and physiopathological changes occurring after RP, as well as to provide a consensus on urinary OARs delineation for prostate cancer (PCa) EBRT in the post-RP setting.
View Article and Find Full Text PDF